Financial Data and Key Metrics Changes - In 2025, WuXi AppTec achieved total revenue of RMB 45.46 billion, with revenue from continuing operations growing 21.4% year-over-year to RMB 43.42 billion [6][20] - Adjusted non-IFRS net profit grew 41.3% year-over-year to RMB 14.96 billion, with a non-IFRS net profit margin improving 5.9 percentage points to 32.9% [6][21] - The adjusted non-IFRS gross profit reached RMB 21.89 billion, with a gross profit margin expanding to 48.2%, up 6.6 percentage points year-over-year [20] Business Line Data and Key Metrics Changes - WuXi Chemistry revenue grew 25.5% year-over-year to RMB 36.47 billion, with an adjusted non-IFRS gross profit margin of 52.3% [10] - Small molecule D&M business revenue increased 11.4% year-over-year to RMB 19.92 billion [11] - TIDES revenue nearly doubled, growing 96% year-over-year to RMB 11.37 billion, with a backlog growth of 20.2% [15] Market Data and Key Metrics Changes - Revenue from the U.S. market grew 34.3% year-over-year, while Japan, Korea, and other regions grew 4.1% [7] - Europe and China experienced declines due to fluctuations in project delivery timing [7] Company Strategy and Development Direction - The company remains focused on its integrated CRDMO core business, aiming to enhance global capabilities and operational efficiency [24] - WuXi AppTec plans to maintain a cash dividend distribution plan totaling RMB 5.7 billion in 2026, with a 30% annual cash dividend payout ratio [26] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining rapid business growth, expecting total revenue to reach RMB 51.3 billion to RMB 53 billion in 2026, with continuing operations revenue growing 18%-22% year-over-year [24] - The company is closely monitoring geopolitical situations and their potential impact on operations, emphasizing a mature and diversified procurement network [32][60] Other Important Information - WuXi AppTec achieved MSCI AAA and CDP Climate Change A ratings in 2025, reflecting its commitment to sustainability [8] - The company completed 741 quality audits and inspections in 2025, maintaining high standards for quality and compliance [9] Q&A Session Summary Question: Impact of currency exchange on guidance - Management acknowledged the impact of FX movements but emphasized strong visibility in their CRDMO business model [30] Question: Geopolitical impact on margins - Management noted that while there are potential risks to raw material costs, they have not seen direct impacts on operations [32] Question: TIDES CapEx and future modalities - Management indicated that while peptide demand remains high, they are also seeing growth in oligonucleotides and complex small molecules [34] Question: Client outsourcing strategy changes - Management stated that large pharma continues to manufacture internally but they remain committed to improving capabilities and providing services [36] Question: Current utilization rate of small molecule capacity - Management highlighted their ability to provide high-quality data, which drives business for their Biology and Testing segments [38] Question: FDA's new trial requirements - Management believes that regulatory streamlining will benefit patients and potentially increase demand for drug substances [40] Question: Positioning in oral small molecule GLP-1 CDMO business - Management confirmed strong growth in the small molecule sector, particularly in GLP-1 drugs [47] Question: Revenue breakdown and geographical mix - Management noted strong growth across all regions, with a focus on customer needs driving geographic revenue growth [49][50] Question: Sustainability of TIDES growth - Management expressed confidence in sustained growth due to a robust pipeline and increasing demand for their products [54] Question: Timeline for new facility contributions - Management stated that new facilities in China can become operational in less than 12 months [57] Question: Impact of Middle East situation on investments - Management reassured that their long-term strategy remains unchanged despite geopolitical tensions [59] Question: Confidence in new orders and revenue guidance - Management expressed confidence in converting backlog into revenue and maintaining growth trajectory [65] Question: WuXi AppTec's position on the 1260H list - Management stated they are confident WuXi AppTec will not be included in the list and will continue to monitor the situation [70]

Financial Data and Key Metrics Changes - The company reported a revenue of RMB 5.9 billion for 2024, reflecting a year-over-year growth of 46.7% [2] - Adjusted net profit margin is projected to be 70%, with a gross profit margin of 22.6% for 2024 [2][6] - The backlog for 2025 is expected to reach USD 1.5 billion, indicating a 50.3% increase compared to 2024 [2] Business Line Data and Key Metrics Changes - The revenue breakdown shows that pre-R&D activities account for 42% of total revenue, with significant contributions from ADC development [2] - The company anticipates strong momentum in ADC development, with a focus on both biotech and pharma sectors [2][3] - The dual-payload ADC format is highlighted as a key innovation area, with expectations for significant market share growth [1][3] Market Data and Key Metrics Changes - The company is targeting a 30% to 35% compound annual growth rate (CAGR) from 2025 to 2030, driven by strong market demand [3][4] - The regional distribution of revenue indicates a strong presence in the US and Europe, collectively contributing to the company's growth strategy [2] Company Strategy and Development Direction - The company is focusing on organic growth and strategic acquisitions to enhance its market position, particularly in the ADC sector [2][3] - There is a strong emphasis on innovation, particularly in payload-linker technology and dual-payload ADC formats, which are expected to drive future revenue [1][3] - The company plans to maintain a robust pipeline with multiple submissions for regulatory approvals anticipated by 2028 [3] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate market volatility and achieve synergy across its operations [4][6] - The outlook for 2025 includes expectations for positive free cash flow and continued investment in CAPEX, projected at RMB 3 billion [2][6] - The management highlighted the importance of maintaining a healthy backlog and ramping up operational capacity to meet future demand [6] Other Important Information - The company is investing heavily in its global footprint, with plans for groundbreaking and commissioning of new GMP sites by 2025 [1][2] - There is a focus on enhancing operational efficiency through AI and technology licensing opportunities [10][11] Q&A Session Summary Question: What is the expected revenue growth for 2025? - The company anticipates a revenue growth of 40% year-over-year for 2025, driven by strong demand in the ADC sector [5] Question: How does the company plan to manage operational capacity? - Management indicated that they are ramping up utilization ratios and maintaining a healthy backlog to ensure operational efficiency [6] Question: What are the key areas of innovation for the company? - The company is focusing on payload-linker technology and dual-payload ADC formats as key areas for innovation and market differentiation [1][3]

Financial Data and Key Metrics Changes - In 2025, the company reported total revenue of CNY 2.06 billion, a 6.5% increase compared to the previous year, with commercialized revenue at CNY 540 million [45][46] - Gross margin increased by 16.1% to CNY 1.47 billion, outpacing revenue growth due to a favorable income mix [46][47] - Total loss for the year was CNY 380 million, slightly higher than the previous year, attributed to increased marketing and sales expenses during the first year of commercialization [47][48] Business Line Data and Key Metrics Changes - The company has four launched products with multiple indications, marking the first year of complete commercialization [22][31] - The commercialization team expanded to nearly 600 people, covering over 300 cities and 1,200 medical institutions in China [12][22] - The company has over 30 R&D projects, with 10+ in clinical development stages and one product in NDA [6][8] Market Data and Key Metrics Changes - Three products and four indications were included in the national medical insurance coverage in 2025, enhancing hospital access [27][60] - The company is focusing on building national channels with core distributors accounting for 90% of business [28][29] - The commercialization strategy includes expanding into 400 professional pharmacies, enhancing patient accessibility [29] Company Strategy and Development Direction - The company aims to advance its differentiated pipeline and address unmet clinical needs while optimizing its ADC platform [20][19] - Strategic collaborations are emphasized to enhance the value of the pipeline and expand business footprint globally [10][20] - The focus is on establishing a leading market position in second-line treatments for non-small cell lung cancer and HR-positive breast cancer [62][63] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in doubling sales in 2026, driven by successful commercialization efforts and product approvals [66] - The company is optimistic about the future, with plans to enhance team capabilities and expand market coverage [66][70] - Management highlighted the importance of data superiority and compliance in driving market access and sales growth [60][63] Other Important Information - The company raised $250 million through H-share placement in 2025 and was included in several global equity indices [13][52] - R&D expenditure was CNY 1.32 billion, a 9.4% increase from the previous year, reflecting stable investment in business expansion [50][51] - The company has a healthy debt-to-asset ratio, with total liabilities at CNY 1.12 billion [53] Q&A Session Questions and Answers Question: What is the expected revenue from licensing and how does it relate to R&D expenses? - Management noted that licensing revenue is accounted for differently and does not correspond directly to R&D expenses, as reimbursement logic varies [67] Question: What are the sales guidance for products other than 264? - Management indicated that 140 has good progress and opportunities due to its unique head-to-head study, while 166 and 167 are also expected to perform well [73][75] Question: When will data for first-line lung cancer be available? - Management anticipates data readouts for first-line lung cancer in Q4 during the ASCO meeting, with ongoing studies expected to yield positive results [57][59]

Financial Data and Key Metrics Changes - In 2025, the company reported total revenue of CNY 2.06 billion, a 6.5% increase compared to the previous year, with commercialized revenue at CNY 540 million [45][46] - Gross margin increased by 16.1% to CNY 1.47 billion, benefiting from a favorable income mix [46][47] - Total loss for the year was CNY 380 million, slightly higher than the previous year, attributed to increased marketing and sales expenses due to the first year of commercialization [47][48] Business Line Data and Key Metrics Changes - The company has four products launched with multiple indications, marking the first year of complete commercialization [22][31] - The commercialization team has expanded to nearly 600 people, covering over 300 cities and 1,200 medical institutions in China [12][22] - The company has successfully included three products in the national reimbursement catalog (NRDL) [27][28] Market Data and Key Metrics Changes - The company has established partnerships with major distributors, accounting for 90% of its business, and expanded its presence in over 400 professional pharmacies [28][29] - The commercialization strategy focuses on brand building and expanding access to hospitals and pharmacies, with a goal to double sales in 2026 [22][67] Company Strategy and Development Direction - The company aims to advance its differentiated pipeline and address unmet clinical needs while optimizing its ADC platform [20][64] - Strategic collaborations are emphasized to enhance the value of the pipeline and expand commercial partnerships globally [10][20] - The focus is on developing new targets and integrating ADC with immunotherapy for enhanced efficacy [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving significant growth in commercialization, particularly after successful NRDL negotiations [68] - The company anticipates that NRDL revenue will account for over 80% of total revenue in the coming year [67] - The management highlighted the importance of building a strong commercial team to navigate the competitive landscape [22][68] Other Important Information - The company has a robust pipeline with over 30 R&D projects, including several in clinical development stages [6][10] - The company raised $250 million through H-share placement in 2025, enhancing its cash reserves to CNY 4.6 billion [13][52] Q&A Session Questions and Answers Question: What is the timeline for data availability on first-line lung cancer trials? - Management indicated that data for the first-line trials may be available by Q4 this year during the ASCO meeting [55][59] Question: What is the expected revenue from licensing and how does it relate to R&D expenses? - Management clarified that licensing revenue is accounted for differently and does not correspond directly to R&D expenses [70] Question: How will the staffing for breast cancer and lung cancer teams be adjusted? - The company plans to increase staffing for the lung cancer team due to its larger patient population, while maintaining a separate focus for breast cancer [72]

Financial Data and Key Metrics Changes - In 2025, the company reported total revenue of CNY 2.06 billion, a 6.5% increase compared to the previous year, with commercialized revenue at CNY 540 million [42][43] - Gross margin increased by 16.1% to CNY 1.47 billion, outpacing revenue growth due to a favorable income mix [43][44] - Total loss for the year was CNY 380 million, slightly higher than the previous year, attributed to increased marketing and sales expenses during the first year of commercialization [44][45] Business Line Data and Key Metrics Changes - The company has four launched products with multiple indications, including TROP-2 ADC and HER2 ADC, which have been successfully included in the national reimbursement catalog [4][10] - The commercialization team has expanded to nearly 600 people, covering over 300 cities and 1,200 medical institutions in China [11][19] - The company has over 30 R&D projects, with 10+ in clinical development stages and one in NDA [4][5] Market Data and Key Metrics Changes - The company has established partnerships for global phase III clinical trials, covering various cancers, including lung and breast cancer [8][9] - The commercialization efforts have led to positive prescriptions and recognition from international and domestic experts, with over 1,200 academic meetings held in 2025 [20][21] - The company is focusing on expanding its market access through national channels and professional pharmacies, with a significant increase in pharmacy coverage [25][26] Company Strategy and Development Direction - The company aims to advance its differentiated pipeline and address unmet clinical needs, focusing on innovative drug development and commercialization strategies [18][59] - There is a strong emphasis on international collaboration and partnerships to maximize the value of the pipeline and expand business footprints outside China [8][18] - The strategy includes a focus on combination therapies and expanding ADC technology to non-oncology diseases [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercialization efforts, anticipating a doubling of sales in 2026 compared to 2025 [62] - The company is optimistic about the inclusion of more products in the NRDL, which is expected to significantly boost revenue [60][61] - Management highlighted the importance of building a strong commercial team to navigate the competitive landscape and ensure successful market access [19][21] Other Important Information - The company raised $250 million through H-share placement in 2025, contributing to a significant increase in cash reserves [49] - The total assets reached close to CNY 6 billion, a 40% increase from the previous year, with cash and financial assets amounting to CNY 4.6 billion [48][49] - The company has made significant progress in clinical trials, with multiple studies showing promising results for various cancer treatments [28][29] Q&A Session Summary Question: What is the expected timeline for data readouts from ongoing clinical trials? - Management indicated that data for first-line lung cancer trials is expected to be available by Q4 this year, with ongoing studies showing promising results [51][52] Question: How does the company view the impact of NRDL price adjustments on revenue? - The CFO clarified that the revenue reported includes adjustments related to NRDL pricing, and the actual revenue before adjustments would be higher [51][52] Question: What are the sales expectations for products not yet included in NRDL? - Management expressed optimism for A140, anticipating rapid ramp-up post-hospital listing, while A166 will require a differentiated pricing strategy due to market competition [67][70]

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, increased to RMB 18.6 million from 0 in the previous year, primarily due to an upfront payment from an intellectual property license and technology transfer agreement with Joincare Group [21] - Other income decreased by RMB 72.6 million or 51.3% to RMB 68.8 million compared to RMB 141.4 million in 2024, mainly due to lower bank interest income and changes in government grants [21][22] - Research and development expenses declined by 14.8% to RMB 212.9 million from RMB 249.8 million in 2024, reflecting cost control measures [22][23] - Administrative expenses were RMB 199.5 million, a decrease of 28.5% compared to RMB 153.2 million in 2024, attributed to lower employee costs and adjustments in management compensation [23] Business Line Data and Key Metrics Changes - The company remains focused on advancing its HBV functional cure program, which is the top clinical priority, with key data reported and studies progressing towards registrational development [3][4] - The partnership with Joincare Group for soralimixin allows the company to prioritize resources on HBV programs while advancing the non-HBV portfolio [4][6] Market Data and Key Metrics Changes - The company is leveraging the strong research ecosystem in China to enhance its discovery capabilities, with new research infrastructure established in Beijing and Shanghai [9][36] - The company is exploring partnership opportunities for its HIV program and soralimixin rights in China, indicating a strategic approach to market expansion [32][36] Company Strategy and Development Direction - The company is sharpening its portfolio focus and expanding discovery capabilities, including integrating AI-enabled discovery tools into research workflows [4][8] - A disciplined partnering strategy is being employed to advance non-core assets while maintaining focus on areas with the strongest near-term opportunities [10][11] - The company aims to align management incentives with long-term shareholder value by significantly reducing senior management's annual bonuses [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the HBV program's potential, with important data expected to emerge in the coming months to inform future development stages [19][39] - The company is committed to maintaining a strong cash position, with bank deposits and cash equivalents amounting to RMB 1,941 million, expected to support operations beyond 2028 [22] Other Important Information - The company has built a robust internal discovery platform and is expected to nominate key new programs from its discovery efforts this year [4][9] - The company is open to both partnerships and self-development for its discovery programs, depending on expertise and market potential [37] Q&A Session Summary Question: Expectations for data from ENRICH and ENHANCE studies - Management expects data to emerge throughout the year, looking for immunologic priming effects and enhanced response rates in specific patient subgroups [26][27][28] Question: Focus areas for expanded discovery capabilities - The company is exploring candidates beyond infectious diseases, targeting chronic diseases with unmet medical needs, with specific areas to be disclosed later [30][31] Question: Updates on partnering strategy for non-core assets - The company continues to explore partnerships for its HIV program and soralimixin rights in China, with ongoing discussions with potential partners [32]

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, increased to CNY 18.6 million from 0 in the previous year, primarily due to an upfront payment from a licensing agreement with Joincare Group [21] - Other income decreased by CNY 72.6 million or 51.3% to CNY 68.8 million compared to CNY 141.4 million in 2024, mainly due to lower bank interest income and changes in government grants [21][22] - Research and development expenses declined by 14.8% to CNY 212.9 million from CNY 249.8 million in 2024, reflecting cost control measures [22][23] - Administrative expenses were CNY 199.5 million, a decrease of 28.5% compared to CNY 153.2 million in 2024, attributed to lower employee costs and adjustments in management compensation [23] Business Line Data and Key Metrics Changes - The company focused on advancing its HBV clinical programs, which remain the top clinical priority, with key data reported and studies advancing towards registrational pathways [3][4] - The partnership with Joincare Group for soralimixin allows the company to prioritize resources on HBV programs while advancing non-HBV assets [4][6] Market Data and Key Metrics Changes - The company is leveraging China's strong research ecosystem to enhance its discovery capabilities, with new research infrastructure established in Beijing and Shanghai [9][10] - The collaboration with OpenBench integrates AI-enabled drug discovery tools, enhancing the company's ability to analyze biological targets and design therapeutic molecules [10] Company Strategy and Development Direction - The company aims to maintain strong alignment with shareholder interests by reducing senior management's annual bonuses significantly, reinforcing the link between management incentives and long-term shareholder value [5] - The strategy includes a combination-based approach for HBV treatment, focusing on BRII-179 and elebsiran, with ongoing Phase 2b studies to evaluate their effectiveness [12][18] - The company is exploring partnership opportunities for its HIV program and other non-core assets, indicating a disciplined partnering strategy [6][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong cash position, expecting current cash to support operations beyond 2028 while continuing to invest in core programs [22][23] - The company anticipates important milestones for its HBV program in the coming year, with data expected to inform the next stage of development [19][39] Other Important Information - The company has built a robust internal discovery platform and is expanding its capabilities to support future pipeline development [9][24] - The focus on chronic diseases and unmet medical needs indicates a strategic shift beyond infectious diseases [31][36] Q&A Session Summary Question: Expectations for data from ENRICH and ENHANCE studies - Management expects data to emerge throughout the year, looking for immunologic priming effects and enhanced response rates in specific patient subgroups [26][27] Question: Focus areas for expanded discovery capabilities - The company is exploring candidates in chronic diseases and common diseases with unmet medical needs, with specific areas to be disclosed later [30][31] Question: Updates on partnering strategy for non-core assets - The company continues to explore partnerships for its HIV program and other assets, with ongoing discussions with potential partners [32][36]

Financial Data and Key Metrics Changes - In 2025, the company's revenue increased to CNY 18.6 million from 0 in the previous year, primarily due to an upfront payment from a licensing agreement with Joincare Group [20] - Other income decreased by CNY 72.6 million or 51.3% to CNY 68.8 million compared to CNY 141.4 million in 2024, mainly due to lower bank interest income and changes in government grant income [21] - Research and development expenses declined by 14.8% to CNY 212.9 million from CNY 249.8 million in 2024, reflecting cost control measures [22] - Administrative expenses were CNY 199.5 million, a decline of 28.5% compared to CNY 153.2 million in 2024, attributed to lower employee costs and organizational optimization [23] - As of December 31, 2025, cash and cash equivalents were CNY 1,941 million, expected to support operations beyond 2028 [22] Business Line Data and Key Metrics Changes - The company focused on advancing its HBV functional cure program, which remains its top clinical priority, with key data reported and studies progressing towards registrational pathways [3][4] - The partnership with Joincare Group for soralimixin allows the company to prioritize resources on HBV programs while advancing non-HBV assets [4][5] Market Data and Key Metrics Changes - The company is leveraging China's strong research ecosystem to enhance its discovery capabilities, establishing labs in Beijing and Shanghai to support early-stage drug discovery [9][36] - The company is exploring partnership opportunities for its HIV program and other non-core assets, indicating a strategic approach to market engagement [32][38] Company Strategy and Development Direction - The company aims to maintain strong alignment with shareholder interests by reducing senior management's annual bonuses to approximately one quarter of their original level [5] - The strategy includes a disciplined partnering approach for non-HBV assets while focusing on areas with the strongest near-term opportunities [10][11] - The company plans to introduce new programs from its discovery platform and define its development strategy around them [24][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the HBV program's potential, expecting important data to emerge later this year to inform the next stage of development [40] - The company is aware of the competitive landscape and aims to differentiate its offerings while exploring the potential of its expanded discovery capabilities [29][36] Other Important Information - The company has made significant investments in building its internal research capabilities and integrating AI-enabled discovery tools into its workflow [8][9] - The company is open to both internal development and partnerships for its discovery programs, depending on expertise and market potential [38] Q&A Session Summary Question: Expectations for data from ENRICH and ENHANCE studies - Management expects data to emerge throughout the year, looking for immunologic priming effects and enhanced response rates in the ENRICH study, and a 10% or better response in the ENHANCE study compared to previous results [26][27][28] Question: Focus areas for expanded discovery capabilities - The company is expanding beyond infectious diseases to include chronic diseases with unmet medical needs, with specific areas to be disclosed later [30][31] Question: Updates on partnering strategy for non-core assets - The company continues to explore partnerships for its HIV program and other assets, with ongoing discussions with potential partners [32]

Financial Data and Key Metrics Changes - In Q4, the company returned to positive net sales growth with a reported increase of 2.2% and approximately 1% on a constant currency basis [3][4] - Gross margin improved to 60.3%, a 10-basis point increase from the previous year, attributed to regional mix and effective tariff mitigations [4][31] - Adjusted EBITDA margin was 20.3% for Q4, maintaining a strong performance while investing in new store openings [32] Business Line Data and Key Metrics Changes - The direct-to-consumer (D2C) business saw strong growth, with D2C e-commerce up 12% and D2C blended sales up 5.2% [12] - Non-travel categories grew by 6.7% year-over-year, now representing 37.6% of total sales [13] - Travel sales experienced a slight decrease of 2.2% compared to the previous year, but showed sequential improvement from -5.3% [14] Market Data and Key Metrics Changes - Asia showed significant improvement with a 5.1% growth on a constant currency basis in Q4, driven by strong performances in China, Korea, India, and Japan [8][9] - North America remained challenging but showed sequential improvements, particularly in the U.S. and Canada [9] - Europe experienced steady growth at 1% for both quarters, with D2C retail up 4.4% and e-commerce up over 9% [9] Company Strategy and Development Direction - The company plans to focus on amplifying brand awareness, enhancing digital capabilities, and expanding into lifestyle bags and accessories [15][18] - Marketing spend is expected to increase to 6.5% of net sales in 2026 to support strategic priorities [40] - The company is preparing for a dual listing in the U.S. to enhance shareholder value [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth driven by travel demand and strategic execution [38] - The ongoing conflict in the Middle East is expected to impact Q1 sales, with a forecast of flat growth on a constant currency basis [39] - The company remains focused on maintaining strong gross margins despite external uncertainties [39] Other Important Information - The company generated strong adjusted free cash flow of $246 million for the year, with a healthy balance sheet showing a net debt position of approximately $1.1 billion [35] - The company received recognition for sustainability efforts, ranking 74th in Time's World's Best Companies in Sustainable Growth for 2025 and 2026 [25] Q&A Session Summary Question: Performance by market and resilience trends - Management noted sequential improvement across all business areas, with specific growth in Japan, Korea, and China, while the Middle East faced challenges [47][48] Question: Cost pressures due to Middle East conflicts - Management acknowledged potential short-term impacts on shipping and raw material costs but emphasized their ability to manage inventory and maintain margins [49][50] Question: Margin expectations for Q1 and store expansion plans - Management indicated that gross margins are expected to remain strong, with store expansions focused on Asia and Europe, particularly for TUMI [55][56] Question: Revenue trends in North America and wholesale customer sentiment - Management observed that wholesale customers in North America are buying cautiously, with a mixed trend for TUMI and improving performance for other brands [62]

Financial Data and Key Metrics Changes - In Q4, the company returned to positive net sales growth with a reported increase of 2.2% and approximately 1% on a constant currency basis [3][4] - Gross margin improved to 60.3%, a 10 basis point increase from the previous year, attributed to regional mix and brand strength [4][31] - Adjusted EBITDA margin was 20.3% for Q4, maintaining a strong performance while investing in new store openings [32][34] - Adjusted net income for Q4 was $106 million, down from $116 million in the prior year [32] Business Line Data and Key Metrics Changes - The direct-to-consumer (D2C) business saw strong growth, with D2C e-commerce up 12% and D2C blended sales up 5.2% [12] - Non-travel categories grew by 6.7% year-over-year, now representing 37.6% of total sales [13] - Travel category sales decreased by 2.2% compared to the prior year but showed sequential improvement from a negative 5.3% [14] Market Data and Key Metrics Changes - Asia experienced a significant recovery with 5.1% growth on a constant currency basis in Q4, driven by strong performance in China, Korea, India, and Japan [8][9] - North America showed sequential improvement, although still facing challenges from prior year comparisons [9] - Europe maintained steady growth at 1% for both quarters, with strong D2C performance particularly in Q4 [9] Company Strategy and Development Direction - The company plans to focus on four strategic pillars: amplifying brand awareness, winning in digital, seizing opportunities in lifestyle bags, and enhancing product development [15][17] - Marketing spend is expected to increase to 6.5% of net sales in 2026 to support these strategic priorities [18][40] - The company is preparing for a dual listing in the U.S. to enhance shareholder value [29][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth driven by travel demand and strategic execution [38] - The ongoing conflict in the Middle East is expected to impact Q1 sales, with a forecast of flat growth on a constant currency basis [38][39] - The company aims to maintain strong gross margins despite uncertainties in the market [39] Other Important Information - The company generated strong adjusted free cash flow of $246 million for the year, with $170 million in Q4 [35] - The balance sheet remains healthy with a net debt position of approximately $1.1 billion [35] - The company received recognition for sustainability efforts, ranking 74th in Time's World's Best Companies in Sustainable Growth [25] Q&A Session Summary Question: Performance by market and resilience trends - Management noted sequential improvement across all business areas, with specific impacts in the Middle East and resilience in Japan, Korea, and China [47][48] Question: Cost pressures from Middle East conflicts - Management acknowledged early signs of cost impacts, particularly in shipping and raw materials, but emphasized their ability to manage margins effectively [49][50] Question: Margin expectations for Q1 and store expansion plans - Margins are expected to remain stable in Q1, with store expansions focused on Asia and Europe, particularly for TUMI [54][56] Question: Revenue trends in North America and wholesale customer sentiment - North America is experiencing a mixed trend, with sell-through strong but wholesale customers remaining cautious [62] Question: Shareholder return expectations post dual listing - The company plans to maintain a dividend payout ratio of around 45% of adjusted net income and will evaluate share buybacks after the dual listing [63][64]